Malcolm Rowland

发表

Physiologically-based pharmacokinetics in drug development and regulatory science.

Malcolm Rowland, Carl Peck, Geoffrey Tucker, 2011, Annual review of pharmacology and toxicology.

Empirical versus mechanistic modeling: Comparison of an artificial neural network to a mechanistically based model for quantitative structure pharmacokinetics relationship

Malcolm Rowland, Ivan Nestorov, I. Petrov, 1999 .

Symbols in pharmacokinetics

Malcolm Rowland, Geoffrey Tucker, G. Tucker, 1980, Journal of Pharmacokinetics and Biopharmaceutics.

Lumping of Whole-Body Physiologically Based Pharmacokinetic Models

Malcolm Rowland, Ivan A. Nestorov, Philip A. Arundel, 1998, Journal of pharmacokinetics and biopharmaceutics.

Editorial to the Second Issue Dedicated to Lewis Sheiner

Malcolm Rowland, 2006, Journal of Pharmacokinetics and Pharmacodynamics.

Dedication to Professor Leslie Z. Benet: 50 Years of Scientific Excellence and Still Going Strong!

Malcolm Rowland, David E. Smith, Gordon L. Amidon, 2012, Pharmaceutical Research.

British Pharmaceutical Conference 1993. Science proceedings, 130th meeting. Chiltern, September 21-24, 1993. Abstracts.

Malcolm Rowland, 1993, The Journal of pharmacy and pharmacology.

Physiologically based pharmacokinetics in Drug Development and Regulatory Science: A workshop report (Georgetown University, Washington, DC, May 29–30, 2002)

Malcolm Rowland, Carl Peck, Luc Balant, 2004, AAPS PharmSci.

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution.

Malcolm Rowland, Thierry Lavé, Volker Fischer, 2011, Journal of pharmaceutical sciences.

Incorporating measures of variability and uncertainty into the prediction of in vivo hepatic clearance from in vitro data.

Malcolm Rowland, Ivan Nestorov, Ivelina Gueorguieva, 2002, Drug metabolism and disposition: the biological fate of chemicals.

Past, Present, and Future of Bioequivalence: Improving Assessment and Extrapolation of Therapeutic Equivalence for Oral Drug Products.

Malcolm Rowland, Rodrigo Cristofoletti, Amin Rostami-Hodjegan, 2018, Journal of pharmaceutical sciences.

Use of microdosing to predict pharmacokinetics at the therapeutic dose: Experience with 5 drugs

Malcolm Rowland, Johannes Kneer, M. Rowland, 2006, Clinical pharmacology and therapeutics.

Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications

Malcolm Rowland, Thomas N. Tozer, M. Rowland, 1980 .

Prediction of In Vivo Tissue Distribution from In Vitro Data 1. Experiments with Markers of Aqueous Spaces

Peter Ballard, Malcolm Rowland, David E. Leahy, 2000, Pharmaceutical Research.

Kinetics of drug-drug interactions

Malcolm Rowland, M. Rowland, Shaikh B. Matin, 1973, Journal of Pharmacokinetics and Biopharmaceutics.

Lead PK commentary: predicting human pharmacokinetics.

Leslie Z Benet, Malcolm Rowland, L. Benet, 2011, Journal of pharmaceutical sciences.

Clearance concepts in pharmacokinetics

Malcolm Rowland, Leslie Z. Benet, L. Benet, 1973, Journal of Pharmacokinetics and Biopharmaceutics.

Rodgers T, Rowland M. 2006. Physiologically‐based Pharmacokinetic Modeling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95:1238–1257.

Malcolm Rowland, Trudy Rodgers, 2007 .

Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective

Malcolm Rowland, Shinji Yamazaki, Jun Chen, 2018, Clinical pharmacology and therapeutics.

Impact of the pharmaceutical sciences on health care: a reflection over the past 50 years.

Malcolm Rowland, Christian R Noe, C. Noe, 2012, Journal of pharmaceutical sciences.

Cyclosporine Inhibition of Hepatic and Intestinal CYP3A4, Uptake and Efflux Transporters: Application of PBPK Modeling in the Assessment of Drug-Drug Interaction Potential

Malcolm Rowland, Michael Gertz, Aleksandra Galetin, 2012, Pharmaceutical Research.

Physiologically Based Pharmacokinetics of Cyclosporine A: Reevaluation of Dose–Nonlinear Kinetics in Rats

Ryosei Kawai, Malcolm Rowland, Chiaki Tanaka, 1999, Journal of Pharmacokinetics and Biopharmaceutics.

Commentary on ACCP Position Statement on the Use of Microdosing in the Drug Development Process

Malcolm Rowland, M. Rowland, 2007, Journal of clinical pharmacology.

Population pharmacokinetics and pharmacodynamics of warfarin in healthy young adults

Malcolm Rowland, Leon Aarons, L. Aarons, 1993 .

Introduction to Pharmacokinetics and Pharmacodynamics: The Quantitative Basis of Drug Therapy

Malcolm Rowland, Thomas N. Tozer, M. Rowland, 2006 .

Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability.

Malcolm Rowland, Ole J Bjerrum, Brian Houston, 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Tissue distribution of basic drugs: accounting for enantiomeric, compound and regional differences amongst beta-blocking drugs in rat.

Malcolm Rowland, M. Rowland, D. Leahy, 2005, Journal of pharmaceutical sciences.

Tissue lipids and drug distribution: dog versus rat.

Malcolm Rowland, Hannah M Jones, M. Rowland, 2012, Journal of pharmaceutical sciences.

Physiologic modeling of cyclosporin kinetics in rat and man

Malcolm Rowland, M. Rowland, A. Bernareggi, 1991, Journal of Pharmacokinetics and Biopharmaceutics.

Pharmacokinetics of Acetylsalicylic Acid and Salicylic Acid After Intravenous Administration in Man

Malcolm Rowland, Sidney Riegelman, M. Rowland, 1968 .

A dispersion model of hepatic elimination: 2. Steady-state considerations-influence of hepatic blood flow, binding within blood, and hepatocellular enzyme activity

Michael S. Roberts, Malcolm Rowland, M. Rowland, 1986, Journal of Pharmacokinetics and Biopharmaceutics.

Physiologically based pharmacokinetic study on a cyclosporin derivative, SDZ IMM 125

Ryosei Kawai, Malcolm Rowland, Jean-Louis Steimer, 1994, Journal of Pharmacokinetics and Biopharmaceutics.

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance.

Malcolm Rowland, Thierry Lavé, Rhys D O Jones, 2011, Journal of pharmaceutical sciences.

Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers.

Malcolm Rowland, Ole J Bjerrum, J Brian Houston, 2011, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

The Use of Population Pharmacokinetics in Drug Development

France Mentré, Malcolm Rowland, Leon Aarons, 1996, Clinical pharmacokinetics.

Comparison of HT29-18-C1 and Caco-2 Cell Lines as Models for Studying Intestinal Paracellular Drug Absorption

Malcolm Rowland, Geoffrey Warhurst, M. Rowland, 1996, Pharmaceutical Research.

Optimal Design for Multivariate Response Pharmacokinetic Models

Malcolm Rowland, Leon Aarons, Kayode Ogungbenro, 2006, Journal of Pharmacokinetics and Pharmacodynamics.

Human clearance prediction: shifting the paradigm

Malcolm Rowland, Thierry Lavé, Kathryn Chapman, 2009, Expert opinion on drug metabolism & toxicology.

A dispersion model of hepatic elimination: 3. Application to metabolite formation and elimination kinetics

Michael S. Roberts, Malcolm Rowland, M. Rowland, 1986, Journal of Pharmacokinetics and Biopharmaceutics.

Measurement of Binding of Basic Drugs to Acidic Phospholipids Using Surface Plasmon Resonance and Incorporation of the Data into Mechanistic Tissue Composition Equations to Predict Steady-State Volume of Distribution

Malcolm Rowland, Hannah M Jones, Iain Gardner, 2011, Drug Metabolism and Disposition.

Impact of target interactions on small-molecule drug disposition: an overlooked area

Malcolm Rowland, Andrés Olivares-Morales, Thierry Lavé, 2018, Nature Reviews Drug Discovery.

Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29-30, 2002).

Malcolm Rowland, Carl Peck, Luc Balant, 2004, AAPS pharmSci.

Pharmacokinetic considerations of regional administration and drug targeting: Influence of site of input in target tissue and flux of binding protein

Malcolm Rowland, M. Rowland, A. McLachlan, 1996, Journal of Pharmacokinetics and Biopharmaceutics.

Clinical pharmacokinetics : concepts and applications

Malcolm Rowland, Thomas N. Tozer, M. Rowland, 1989 .

Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response

Malcolm Rowland, Alasdair Breckenridge, Bruno Flamion, 2011, Nature Reviews Drug Discovery.

Fuzzy Simulation of Pharmacokinetic Models: Case Study of Whole Body Physiologically Based Model of Diazepam

Malcolm Rowland, I. Nestorov, M. Rowland, 2004, Journal of Pharmacokinetics and Pharmacodynamics.

Importance of target-mediated drug disposition for small molecules.

Malcolm Rowland, Andrés Olivares-Morales, Thierry Lavé, 2018, Drug discovery today.

Reducing Whole Body Physiologically Based Pharmacokinetic Models Using Global Sensitivity Analysis: Diazepam Case Study

Malcolm Rowland, Ivelina Gueorguieva, I. Nestorov, 2006, Journal of Pharmacokinetics and Pharmacodynamics.

PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.

Malcolm Rowland, Thierry Lavé, Rhys D O Jones, 2011, Journal of pharmaceutical sciences.

Physiologically-based Kinetic Modelling (PBK Modelling): Meeting the 3Rs Agenda

Ursula Gundert-Remy, Martin Spendiff, Alan Boobis, 2007, Alternatives to laboratory animals : ATLA.

Microdosing: a critical assessment of human data.

Malcolm Rowland, M. Rowland, 2012, Journal of pharmaceutical sciences.

Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance

Malcolm Rowland, K. Sandy Pang, M. Rowland, 1977, Journal of Pharmacokinetics and Biopharmaceutics.

Mechanistic Approaches to Volume of Distribution Predictions: Understanding the Processes

Malcolm Rowland, M. Rowland, Trudy Rodgers, 2007, Pharmaceutical Research.

A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations

Michael S. Roberts, Malcolm Rowland, M. Rowland, 1986, Journal of Pharmacokinetics and Biopharmaceutics.

Pharmacokinetics of lidocaine and its deethylated metabolite: Dose and time dependency studies in man

Malcolm Rowland, L. Aarons, M. Rowland, 1982, Journal of Pharmacokinetics and Biopharmaceutics.

Physiologically Based Pharmacokinetic Modeling of a Homologous Series of Barbiturates in the Rat: A Sensitivity Analysis

Malcolm Rowland, L. Aarons, I. Nestorov, 1997, Journal of Pharmacokinetics and Biopharmaceutics.

Uncertainty Analysis in Pharmacokinetics and Pharmacodynamics: Application to Naratriptan

Malcolm Rowland, Leon Aarons, Ivelina Gueorguieva, 2005, Pharmaceutical Research.

Optimizing the Science of Drug Development: Opportunities for Better Candidate Selection and Accelerated Evaluation in Humans

Malcolm Rowland, Lawrence J Lesko, Terrence F Blaschke, 2004, Pharmaceutical Research.

Protein binding and hepatic clearance: Discrimination between models of hepatic clearance with diazepam, a drug of high intrinsic clearance, in the isolated perfused rat liver preparation

Malcolm Rowland, George Fleming, M. Rowland, 1984, Journal of Pharmacokinetics and Biopharmaceutics.